Loxo oncology, inc. (LOXO)
CashFlow / TTM
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Net loss

-62,976

-109,231

-127,906

-148,876

-155,442

-99,814

-85,329

-72,398

-58,071

-49,151

-41,291

-35,876

-30,131

-28,103

-23,952

-20,672

0

0

0

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of premium and discounts on investments

-1,578

-801

-241

80

262

404

497

528

514

484

439

391

0

0

0

-

-

-

-

Depreciation of property and equipment

437

263

184

125

113

97

84

77

50

41

30

17

0

0

0

-

-

-

-

Stock-based compensation

37,895

32,009

25,099

19,422

17,243

14,741

10,592

7,960

7,699

6,099

6,447

6,154

4,326

5,196

4,034

3,049

0

0

0

Changes in operating assets and liabilities:
Receivable from collaboration partner

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

2,022

2,603

2,181

3,076

689

979

1,830

-224

1,454

1,788

1,671

1,971

0

0

0

-

-

-

0

Accounts payable

189

2,614

4,543

2,935

808

1,498

495

792

290

262

473

30

524

-161

42

18

0

0

0

Accrued expenses and other current liabilities

28,098

25,378

13,391

8,454

10,008

3,889

7,008

11,499

3,525

3,716

1,160

1,073

0

0

0

-

-

-

-

Deferred revenue

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

234,299

232,840

244,206

107,763

-127,697

-80,164

-68,483

-51,318

-47,447

-40,337

-34,413

-30,182

-25,099

-22,479

-19,839

-17,695

0

0

0

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Investing activities:
Purchases of available-for-sale securities

651,407

704,437

668,619

574,508

401,392

229,326

240,063

163,290

189,749

199,726

166,954

133,730

0

0

0

-

-

-

-

Proceeds from maturing available-for-sale securities

465,979

353,491

232,341

201,136

180,732

140,176

140,853

137,038

143,687

145,666

139,614

116,646

0

0

0

-

-

-

-

Purchase of property and equipment

4,124

3,232

1,434

789

410

170

109

237

245

253

302

93

0

0

0

-

-

-

-

Net cash used in investing activities

-189,552

-354,178

-437,712

-374,161

-221,070

-89,320

-99,319

-26,489

-46,307

-54,313

-27,642

-17,177

0

0

0

-

-

-

-

Financing activities:
Proceeds from issuance of redeemable convertible preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43,178

0

0

0

Proceeds from issuance of common stock, net

-

-

-

375,307

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

10,629

8,376

2,869

2,740

2,266

1,884

632

1,273

0

0

0

-

-

-

-

167

0

0

0

Net cash provided by financing activities

10,629

8,406

248,790

378,047

377,573

377,161

168,751

40,006

0

0

0

-

-

-

-

115,711

0

0

0

Net (decrease) increase in cash, cash equivalents, and restricted cash

55,376

-112,932

55,284

111,649

28,806

207,677

949

-37,801

17,520

16,271

10,292

24,247

-84,212

-14,669

10,322

28,936

0

0

0

Unrealized gain on available for sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0